Companies Double Down on Prediction Market Investments Amid Regulatory Uncertainty German Business Morale Unexpectedly Improves in May Amid Iran War Energy Disruptions Europes AI Trade Dependency Could Pose Strategic Risks Report Warns DeEscalation Headlines Pressure Gold Prices as Memorial Day Weekend Approaches RVNL Shares Fall as Q4 Profit Declines 43 YearonYear Kimi Antonelli Secures Historic Fourth Consecutive F1 Win in Canada Championship Standings Shift IQST Q4 2025 Earnings Massive EPS Miss Highlights Ongoing Challenges SIGA Technologies Q1 2026 Earnings Narrowed Loss Amidst Absence of Key Revenue Disclosures SAP Q1 2026 Earnings Modest EPS Beat Amidst Cloud Growth Momentum FULTP Q1 2026 Earnings Preferred Stock Reports EPS Beat Amid Steady Performance ROIV Q1 2026 Earnings WiderThanExpected Loss Highlights PreRevenue Pipeline Costs Lightbridge Corporation LTBR Q1 2026 Earnings Net Loss of 020 Per Share Continues Development Phase Envista Holdings NVST Slips Slightly as Stock Navigates Key Support and Resistance Levels LaFayette Acquisition Corp Rights LAFAR Decline Deepens Stock Hits 012 Testing Key Support Winchester Bancorp Inc WSBK Edges Lower Amid Light Trading Key Levels in Focus DFP Holds Steady Near 20 as Preferred Income Fund Displays Resilience Spring Valley Acquisition Corp IV Units SVIVU Hold Steady at 1026 Amid Quiet Trading KTCC Q1 2026 Earnings Negative EPS Highlights Ongoing Operational Challenges Ategrity Specialty Insurance Company Holdings ASIC Q1 2026 Earnings EPS Beats Estimates by 22 Shares Edge Higher MGE Energy Q1 2026 Earnings EPS Beat Driven by Operational Strength Encore Capital Group Q1 2026 Earnings Strong EPS Beat of 2646 Amid Stock Decline HEPS Q1 2026 Earnings Negative EPS and No Revenue Disclosure Weigh on Sentiment Shares Decline 387 SANA Q1 2026 Earnings Narrower Loss Per Share Surprises on Operational Progress Novartis Raises FullYear Sales and Profit Guidance Signaling Strong Operational Momentum BioRad Q1 2026 Earnings Earnings Miss Estimates Despite Stock Rally Jupiter Neurosciences Jumps 135 as Speculative Interest Builds in SmallCap Biotech